Market News AIOpen the app

UBS has cut its price target for Syndax Pharmaceuticals to $31, down from $33.

OpinionRead the original at marketscreener.com
Neutral

UBS lowered its target from $33 to $31 but kept its Buy rating. The mixed opinion reports no change in Syndax's business, so it does not change the company's outlook.

SNDX · Syndax Pharmaceuticals, Inc.

AI read · Neutral

The AI's read

An analyst's view can shape how investors see Syndax, but this report gives no new information about its medicines or business plans. The lower target and retained Buy rating point in different directions, so neither supports a clear change in the company's outlook.

Get alerts for SNDX

Follow Syndax Pharmaceuticals, Inc. (SNDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SNDX
Free on the App Store and Google Play, or on the web.